A Ternary Synergistic eNOS Gene Delivery System Based on Calcium Ion and L-Arginine for Accelerating Angiogenesis by Maximizing NO Production
Guiming Zhang,Shangcong Han,Lisheng Wang,Yu Yao,Kai Chen,Si Chen
DOI: https://doi.org/10.2147/IJN.S363168
IF: 7.033
2022-05-03
International Journal of Nanomedicine
Abstract:Guiming Zhang, 1, &ast Shangcong Han, 2, &ast Lisheng Wang, 3 Yu Yao, 1 Kai Chen, 4 Si Chen 5 1 Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China; 2 Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266021, People's Republic of China; 3 Department of Molecular Diagnosis and Regenerative Medicine, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China; 4 Department of Clinical Research, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, 300162, People's Republic of China; 5 Department of Anesthesiology, the 991th Hospital of PLA, Xiangyang, 441000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guiming Zhang, Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China, Email Purpose: This study aimed to construct a delivery system based on L-arginine-modified calcium phosphate (CaP) to load eNOS plasmids (peNOS), which could amply nitric oxide (NO) to repair endothelial damage, promote angiogenic activities and alleviate inflammation. Methods: pDNA-loaded CaP nanocomplex (CaP/pDNA) were prepared by co-precipitation method, subsequently modified by L-arginine. The gene transfection efficiency, pro-angiogenic and anti-inflammatory ability were investigated in vivo and in vitro. The therapeutic effect on ischemic hindlimb in vivo was assessed. Results: L-arginine modification augmented the transfection efficiency of CaP/peNOS to elevate the eNOS expression, and then served as NO substrate catalyzed by eNOS. At the same time, calcium ions produced by degradation of CaP carriers enhanced the activity of eNOS. In vitro experiments, the loading capability and transfection performance of R(L)-CaP were confirmed to be superior to that of CaP. Additionally, HUVECs treated with R(L)-CaP/peNOS showed the strongest NO release, cell migration, tube formation and the lowest inflammatory levels compared to the CaP/peNOS and R(D)-CaP/peNOS groups. We also demonstrated the advantages of R(L)-CaP/peNOS in increasing blood reperfusion in hindlimb ischemia mice by accelerating angiogenesis and reducing inflammation, which can be attributed to the highest eNOS-derived NO production. Conclusion: The combination strategy of peNOS transfection, L-arginine supplement and calcium ions addition is a promising therapeutic approach for certain vascular diseases, based on the synergistic NO production. Keywords: gene delivery, nitric oxide, L-arginine, calcium ion, angiogenesis Endothelial dysfunction can trigger and exacerbate a variety of vascular diseases, such as atherosclerosis. 1,2 Atherosclerotic plaques in lower extremity arteries tend to lead to inadequate distal blood supply and, in severe cases, to critical limb ischemia (CLI). 3,4 Accelerating vascular endothelial cells (VECs)-dominant vascular regeneration and alleviating excessive inflammation in affected extremities are effective approaches for the treatment of CLI. 5 Normal VECs regulate vascular tone and maintain vascular functions by acting as a physical barrier and secreting vasodilatory substances, anticoagulants, anti-inflammatory cytokines, and many other active components. As a multifunctional gas signaling molecule released by VECs, nitric oxide (NO) was originally identified as a vasodilator and has been shown to inhibit platelet adhesion and smooth muscle cells (SMCs) proliferation, promote VECs morphogenesis, and reduce inflammatory response. 6 The decrease in NO bioavailability is considered as one of the most important causes of endothelial dysfunction. 7 Hence, a moderate increase in NO levels produced by VECs and their bioavailability is of vital significance in mitigating CLI processes through repairing endothelial damage, enhancing VECs angiogenic activities and reducing pro-inflammatory cytokines. 8,9 Administration of exogenous NO donors can successfully up-regulate intracellular NO levels; however, existing NO donors suffer from deficiencies including disappointing drug release performance, poor bioavailability, and unignored side effects. 10,11 Thoroughly understanding the synthesis mechanism of endogenous NO is valuable for artificially up-regulating its production. 12 Undoubtedly, NO in VECs is generally produced by endothelial nitric oxide synthase (eNOS) catalyzing L-arginine. A growing body of researches is devoted to promoting the release of endogenous NO. -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology